VT-EBV (ViGenCell)

N/A

Report date: 2024/11/18 20:00:28

Base Information

Drug NameVT-EBV (ViGenCell)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsLymphoma, Extranodal NK-T-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesVigencell Inc Catholic University Of Korea

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesVigencell Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, Extranodal NK-T-Cell

Other Information

ATC CodeN/A